Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer. Arlene Siefker-Radtke, MD: Another interesting trial presented at ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Disitamab vedotin achieved ORR 54.9% (HER2-positive) and 52.6% (HER2-low), with complete responses 16.9% and 18.4%, supporting efficacy beyond strictly HER2-amplified tumors. Clinical benefit was ...

The median overall survival was 31.5 months in the disitamab vedotin-toripalimab arm and 16.9 months in the chemotherapy arm. First-line treatment with disitamab vedotin and toripalimab can improve ...

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as ...

YANTAI, China, March 10, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an ...

The objective response rate was 54.9% in the HER2-positive patients and 52.6% in the HER2-low patients. Disitamab vedotin has shown antitumor activity across HER2-expressing subgroups with pretreated, ...

YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium ...

RemeGen Co., Ltd ("RemeGen" or "the Company"), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of ...

(RTTNews) - Biotechnology company Seagen Inc. (SGEN) and Chinese biopharmaceutical company RemeGen Co., Ltd. on Monday said they have entered into a licensing agreement for RemeGen's disitamab vedotin ...

Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...